A 32-year-old primigravida at 28 weeks of gestation presents with asymmetric intrauterine growth restriction (IUGR) confirmed on ultrasound. Doppler studies show abnormal umbilical artery waveforms with elevated pulsatility index. She is hemodynamically stable with normal blood pressure. Which drug is the first-line choice to improve fetal outcomes in this scenario?